The information in this section is intended for visitors outside the United States.
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Fixed-Dose Combination of Emtricitabine/Tenofovir Alafenamide for HIV Treatment
Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Sovaldi® (sofosbuvir) for the Treatment of Genotype 2 Chronic Hepatitis C
Gilead Sciences to Present at the Barclays Global Healthcare Conference on Wednesday, March 11
2014 Annual Review